Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, S. Faderl, MD, A. Ferrajoli, MD, G. Garcia-Manero, MD, J. Burger, MD, E. Schlette, MD, L. Abruzzo, MD, PhD, S. Lerner, MS, BA, M. Keating, MB, BS

Blood (2007) 110 (11): 2065.

https://doi.org/10.1182/blood.V110.11.2065.2065

Published: 2007

Journal Articles

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, Z. Estrov, MD, G. Garcia-Manero, MD, S. Verstovsek, MD, M. Browning, BSN, ADN, S. Lerner, MS, BA, M. Keating, MB, BS

Blood (2007) 110 (11): 628.

https://doi.org/10.1182/blood.V110.11.628.628

Published: 2007

Journal Articles

Surface Antigens Identified by Antibody Microarray That Correlate with IgV H Mutational Status and ZAP70 Expression in CLL.

William G. Wierda, MD, PhD, S. Mulligan, MD, B. Shelvin, L. Belov, PhD, L. Rassenti, PhD, T. Kipps, MD, PhD, S. Lerner, MS, M. Thomas, PhD, H. Kantarjian, MD, M. Keating, MB, BS

Blood (2005) 106 (11): 2944.

https://doi.org/10.1182/blood.V106.11.2944.2944

Published: 2005

Journal Articles

Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL.

William G. Wierda, MD, PhD, S. OBrien, MD, X. Wang, MS, A. Ferrajoli, MD, S. Faderl, MD, D. Thomas, MD, F. Ravandi, MD, K. Do, PhD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MD

Blood (2005) 106 (11): 5012.

https://doi.org/10.1182/blood.V106.11.5012.5012

Published: 2005

Journal Articles

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

William G. Wierda, MD, PhD, X. Wang, MS, S. OBrien, MD, S. Faderl, MD, A. Ferrajoli, MD, D. Thomas, MD, F. Ravandi, MD, J. Cortes, MD, F. Giles, MD, C. Koller, MD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MB BS

Blood (2005) 106 (11): 5018.

https://doi.org/10.1182/blood.V106.11.5018.5018

Published: 2005

Journal Articles

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

William G. Wierda, MD, PhD, S. OBrien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, F. Giles, MD, J. Cortes, MD, D. Thomas, MD, F. Ravandi, MD, G. Garcia-Manero, MD, M. Andreeff, MD, S. Lerner, MS, H. Kantarjian, MD, M. Keating, MD

Blood (2005) 106 (11): 719.

https://doi.org/10.1182/blood.V106.11.719.719

Published: 2005

Journal Articles

Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy

M.J. Keating, S. O’Brien, S. Lerner, C. Koller, M. Beran, L.E. Robertson, E. J Freireich, E. Estey, H. Kantarjian

Blood (1998) 92 (4): 1165–1171.

https://doi.org/10.1182/blood.V92.4.1165

Published: 1998

Journal Articles

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy

S O'Brien, H Kantarjian, M Beran, LE Robertson, C Koller, S Lerner, MJ Keating

Blood (1995) 86 (4): 1298–1300.

https://doi.org/10.1182/blood.V86.4.1298.bloodjournal8641298

Published: 1995

Journal Articles

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]

S O'Brien, H Kantarjian, M Beran, T Smith, C Koller, E Estey, LE Robertson, S Lerner, M Keating

Blood (1993) 82 (6): 1695–1700.

https://doi.org/10.1182/blood.V82.6.1695.1695

Published: 1993

NARROW

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Surface Antigens Identified by Antibody Microarray That Correlate with IgV H Mutational Status and ZAP70 Expression in CLL.

Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL.

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only